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Abstract: NAD(P)H:quinone oxidoreductase 1 (NQO1) is a flavoenzyme upregulated in 
response to oxidative stress and in some cancers.  Its upregulation by compounds has been 
used as an indicator of their potential anti-cancer properties.   In this study we have designed, 
produced and tested a fluorogenic coumarin conjugate which selectively releases highly 
fluorescent 4-methylumbelliferone (4-MU) in the presence of NQO1.  It was found that 
measuring 4-MU release rapidly and specifically quantitated NQO1 levels in vitro and in live 
cells.  Both the substrate and its products freely perfused through cell membranes and were 
non-toxic.  The substrate was very specific with low background, and the assay itself could 
be done in less than 10 minutes.  This is the first assay to allow the quantitation of NQO1 in 
live cells which can then be retained for further experiments. 
 
Abbreviations: 4-MU: 4-methylumbelliferone; NQO1: NAD(P)H:quinone oxidoreductase 1 
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1. Introduction 
NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase [1], vitamin K reductase [2], 
menadione reductase [3]) is a flavoenzyme predominantly present in the cytoplasm, with a 
small amount associated with mitotic spindles in the nucleus [4].  It is a homodimer which 
binds quinones with the co-factor NADH or NADPH, leading to reduction of the quinones by 
a ping-pong mechanism of catalysis [5].  The enzyme has wide ranging roles within the cell.  
It is primarily thought to be an important chemoprotective enzyme which is capable of 
reducing various quinones and aromatic nitro-compounds [6], reducing cellular quinone 
levels and minimizing reactive oxygen intermediates.  It is further capable of regenerating 
ubiquinone and vitamin E [7,8] into anti-oxidants thus forming another important part of the 
cell’s defense system against oxidative stress.  NQO1 can also activate anti-cancer agents 
such as mitomycin C and β-lapachone using the same 2-electron reduction that inactivates 
cell-damaging quinone moieties [9–13].  NQO1 also has a complementary activity to its 
catalytic function in that it can bind the 20S proteasome [14], preventing the proteasome from 
binding and degrading other proteins.   
NQO1 activity is clearly of interest in a number of fields.  It is upregulated in many solid 
tumours [15], and is a potential tumour marker [16] as well as an activator of anti-cancer 
chemotherapeutics [9].  The complementary use of NQO1 as a primary screen for natural 
anticarcinogens such as sulforaphane and chlorogenic acid from broccoli sprouts and green 
coffee beans respectively is also well documented [17,18]. However, the current most 
generally applicable method by which NQO1 is assayed, the Prochaska assay, requires that 
cells are lysed and a cell extract is made to release NQO1 [19], limiting further 
investigations, particularly in situations such as the use of unique, limited patient samples. 
More recent assays have fluorescent products which are retained inside the cell [16,20]. In the 
current work we describe a cell permeable substrate for NQO1 which contains 4-
methylumbelliferone (4-MU) in a quenched fluorescent state.  Cleavage of the quenching 
moiety by active NQO1 within live cells releases the fluorescent 4-MU, which is cell 
permeable.  The amount of 4-MU present in the surrounding medium can be measured in a 
fluorimeter to give a quantitative measure of NQO1 activity without fixing or lysing the cells.  
The non-toxic nature of the substrate and its products uniquely allow further tests such as 
apoptosis assays or flow cytometric analysis to be performed on the same cells as the 
quantitation of NQO1. 
  
2. Methods 
Chemicals and reagents were obtained from Sigma Aldrich Chemical Co, Dorset UK, 
Lancaster Synthesis Ltd, Lancashire, UK and VWR International, Leicestershire, UK. 
HPLC was performed using a ThermoFisher Accela U-HPLC (Ultra-High Pressure Liquid 
Chromatography) System equipped with a C18 reverse-phase column (dimensions: 50x2.1 
mm; particle size 1.9 micron). The chromatograms were analyzed using a PDA (Photo Diode 
Array) system or FL-Plus detector with settings as follows: PMT (low), λex= 360 nm; λem = 
450 nm and processed using ChromQuest software (version 4.2). 
 
Docking of the substrate in the active site of human NQO1 
The three-dimensional structure of the substrate was constructed using ChemDraw (version 
11.0) and the energy minimised. The X-ray crystallographic co-ordinates of human NQO1 
(pdb 1H69) were downloaded from the RCSB Protein Data Bank and revised to provide a 
monomer of the protein with the reduced form of FAD (FADH2) as the bound cofactor. 
Molegro Virtual Docker (MVD version 3) software was used to predict the binding mode of 
the substrate in the active site of the enzyme. The docking procedure was randomised and the 
substrate was docked at 11Å radius around the FAD binding site (active site)20. The 
MolDock optimiser algorithms were used with a maximum of 10 runs and 5000 iterations 
(the docked substrate achieved lowest energy within the set iterations). A maximum of 5 
poses were returned for the substrate in which similar poses were clustered. The top ranked 
pose for the substrate was assigned with regard to its affinity towards the FADH2 (the 
distance of the quinone carbonyl to the pteridine N5 of the FADH2 substructure (Figure 1)) 
and substrate-enzyme active site residue hydrogen bonding interactions. The substrate-
enzyme interactions were visualised using Molegro Molecular Viewer (version 1.2). 
 
Synthesis of the substrate probe 
A mixture of 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid (800 
mg, 3.4 mmol), N,N′-Dicyclohexylcarbodiimide (DCC: 830 mg, 4.0 mmol) and 4-
(dimethylamino)pyridine (DMAP: 42 mg, 0.4 mmol) were sus-pended in dry DCE (20 ml). 
The suspension was stirred for 30 minutes. 4-methylumbelliferone (634 mg, 3.6 mmol) was 
added and the mixture was stirred for a further 24 hours. The resulting suspension was 
filtered and the filtrate was evaporated. 
The formed suspension was filtered, evaporated and redis-solved in ethyl acetate and filtered. 
The organic extract was evaporated and recrystallised from ethyl acetate to yield the product 
as yellow crystals (0.96 g, 69%, mp 143-145ºC uncorr., MS: ESI+  431.2 (M+Na)). 1H NMR 
(CDCl3): d 7.58 (1H, d, ArH, J=5Hz), 7.02 (1H, d, ArH, J=3Hz), 6.98 (1H, d, ArH, J=3Hz), 
6.96 (1H, d, ArH, J=3Hz), 3.29 (2H, s, CH2), 2.41 (3H, s, CH3), 2.18 (3H, s, CH3), 1.94 (3H, 
s, CH3), 1.53 (6H, s, 2xCH3). 
13C NMR (CDCl3): d 190.8, 187.3 (2x quinone C=O), 170.8 
(C=OO), 160.4 (C=O coumarin), 154.1, 152.8, 151.8, 151.5, 142.7, 139.7, 138.8, 125.4, 
117.9, 117.8, 114.6, 110.4 (12x ring C), 47.7 (CH2), 38.4 (C(CH3)2), 29.0 (2x gem-CH3), 18.7 
(CH3), 14.4, 12.6, 12.1 (3xCH3). 
 
HPLC analysis of reaction mixtures of substrate and enzyme 
Initial HPLC was carried out on samples containing substrate (0.1 mM), NADH (0.5 mM, 
Sigma) and 0.5 μg/ml recombinant human NQO1 (Sigma) in phosphate buffered saline (PBS, 
10 mM, pH 7) using a 1-99% acetonitrile gradient and a 2 μl injection volume.  Temperature 
was maintained at 37°C. Reduction of the substrate was rapid and an enzyme concentration 
of 0.2 μg/ml NQO1 was found to be suitable for determining the initial rate of substrate 
reduction. No significant reduction in the area of the peak was observed in the presence of 
either substrate alone or with NADH alone. The rate of reduction in substrate concentration 
was calculated as 5.9 μM/min and when the concentration of the enzyme was halved the rate 
reduced to 1.5 μM/min. This finding demonstrates that the substrate is efficiently reduced by 
NQO1. There was an increase in 4-MU peak area when monitored at 325 nm that matched 
the loss of substrate confirmed by an increase in 4-MU fluorescence peak (data not shown). 
The cut-off point for the UV spectra was initially set between 220-800 nm but when the 
lower wave-length was reduced to 180 nm, the lactone, 4-MU and substrate were quite 
evident above the baseline. The elution times of substrate, lactone and 4-MU were 4.24 min, 
3.10 min and 2.16 min, respectively. 
 
Kinetic studies 
Kinetic studies were performed in a BMG Clariostar microplate reader.  2ng recombinant 
human NQO1 enzyme was added to 500 µM NADH and 0 – 25 µM MTL8-252 in a total of 
100 µl Hanks balanced salt solution (HBSS, Thermo Scientific).  Fluorescence (λex. 360nm, 
λem. 450nm) was read every 15s for 5 minutes, every 30s from 5-10 minutes and every 
minute from 10-30 minutes from the beginning of the assay. Each assay was performed 3-5 
times at 25ºC.  Fluorescence readings were standardised to a standard curve of 4-MU of 
known concentration. 
 
Cell lines and cell culture  
All cells were grown in media supplemented with 10% FCS, 50 U/ml penicillin, 50 mg/ml 
streptomycin and 2 mM L-glutamine.  The human embryonic kidney line 293T was grown in 
DMEM supplemented as above.  The human prostate cancer cell line PC3 was grown in 1:1 
Hams:F12.  The human bladder cancer cell line RT112 (NQO1*1) [21] and colon 
adenocarcinoma line BE (NQO1*2) [22] were grown in RPMI1640 and MEM respectively.  
V79 Chinese Hamster lung epithelial cells transfected with either NQO1 (hDT7 cells) or an 
empty vector (F179 cells) [23] were grown in DMEM as above additionally supplemented 
with 10 µg/ml puromycin.  All cell culture reagents were sourced from Life Technologies.   
 
Western blot 
Western blots were performed with 50µg of cell lysate from cell lines described above.  All 
cell lines were subconfluent at harvest.  Proteins were separated with standard SDS-PAGE 
and transferred onto supported nitrocellulose membrane (BioRad).  The membrane was 
blocked with 5% non-fat milk in Tris buffered saline with 0.1% Tween 20 overnight. NQO1 
was detected with muIgG clone 4D12 (Abcam, UK) at 1:5,000 and secondary polyclonal 
anti-muIgG-HRP (Sigma) at 1:20,000.  The relevant protein bands were visualised with 
Pierce Supersignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
 
Direct fluorescence assay for NQO1 
Cell-free NQO1 was quantitated by resuspending recombinant human NQO1 enzyme with 
500 μM NADH and 5 μM MTL8-252 in 240 μl HBSS and incubating at 37°C for 10 minutes.  
The NADH was then degraded by addition of HCl to 10 mM and further incubation for 5 min 
at 37°C.  The reaction was filtered through a 0.2 μm PTFE filter using a two-piece 1 ml filter 
vial (Thomson Xtreme Vials, Thomson Instrument Company, CA, USA) and 100 μl of 
filtrate added to 20 μl of 2 M aqueous Na2CO3 in a microcuvette (Promega Ltd.).  
Fluorescence was then measured using a portable QuantifluorTM fluorimeter (Promega) (365 
nm Ex/440-470 nm Em).  Cellular NQO1 activity was measured by resuspending the required 
number of cells in a final volume of 250 μl HBSS and adding the desired concentration of 
substrate as a solution in 2.5 μl DMSO.  After 10min at 37°C, the reaction was filtered as 
above and 100 μl of filtrate was transferred to a microcuvette.  4-MU fluorescence intensity 
was maximised by adding 2.5 μl aqueous 2 M Na2CO3 prior to fluorescence measurement.  
The fluorimeter was calibrated using a 4-MU solution of known concentration. 
 
The Prochaska assay 
To determine NQO1 levels by Prochaska assay, confluent RT112 cells were harvested and 
resuspended in HBSS at a density of 107 cells/ml.  Cells were then serially diluted in HBSS 
and either used for a live cell assay as described above or frozen on dry ice for the Prochaska 
assay to retain NQO1 activity and disrupt membranes.  The Prochaska master mix was made 
of 25 mM Tris pH 7.4, 66.6 μg/ml BSA, 0.01% Tween 20, 1 mM glucose-6-phosphate, 30 
μM NADP, 2 U/ml glucose-6-phosphate dehydrogenase, 5 μM FAD and 300 μg/ml MTT, 
with 3 μl of 50 mM menadione added per 5 ml master mix just before beginning the assay.  
After vortexing, the assay was performed at 25ºC with 240 μl of master mix to 10 μl cell 
extract.  After 5 minutes the assay was placed on ice and stopped with 100 μM dicoumarol 
and the absorbance of the assay mixture measured immediately at 600 nm on a Thermo 
Labsystems Multiskan Spectrum. 
 
 
 
Quantitation of NQO1 by NADH consumption. 
Kinetic analysis of menadione and quantitation of NQO1 was performed by quantitating the 
reduction in NADH fluorescence over time. 50ng NQO1 was added to HBSS containing 200 
µM NADH and 5 µM FAD.  For comparison of MTL8-252 and menadione, serial dilutions 
of menadione were then titrated into the mixture and NADH fluorescence (λex. 340nm, λem. 
440nm) was monitored at 15s intervals for 5 minutes, then at 1minute intervals for 5 minutes.  
Final readings were taken at 10 minutes.  Similarly, titration of the NADH assay was 
performed by serially diluting NQO1 enzyme and adding master mix to a final concentration 
of 200 µM NADH, 5 µM FAD and 50 µM menadione in HBSS.  Fluorescence readings were 
taken as described above. 
 
Determination of toxicity 
To determine toxicity, 24 well plates were seeded with 5 x 105 RT112 cells in phenol-red free 
DMEM containing 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine and 10% 
FCS.  Following overnight incubation, cells were treated with 10 μl DMSO containing the 
standard concentration of MTL8-252 (5 μM), ten times the standard concentration (50 μM), 
or no MTL8-252.  Cells were incubated for the times indicated and viability measured using 
the CellTiterGlo assay (Promega) according to the manufacturer’s instructions. 
 
Cell retention of MTL8-252 and 4-MU 
To examine cell retention of MTL8-252, 105 F179 or hDT7 cells were suspended in 100µl 
HBSS containing 20µM MTL8-252 and incubated at 37ºC for 5 minutes.  The cells were 
removed by centrifugation (5 min, 500rcf) and the supernatant added to 2.5µl of 2M Na2CO3 
for reading of 4-MU fluorescence.  Cells were rinsed once in 1ml HBSS and collected by 
centrifugation as bove.  They were then resuspended in 100µl fresh HBSS and incubated for 
5 minutes before centrifuging as previously and fluorescence readings made of the 
supernatant.  The process was repeated twice.  After the final centrifugation the cell pellet 
was lysed by 3 freeze-thaw cycles in which the pellet was frozen on dry ice then thawed 
rapidly at 37ºC. The cell pellet was incubated with an excess of NQO1 and NADH (10µg/ml 
and 200µM respectively) and then acidified by adding HCl to 50mM.  After 10 minutes, 20 
µl of 2M Na2CO3 was added and fluorescence of the solution determined in the Quantifluor 
fluorimeter.   
 
  
Results and Discussion 
Design of the NQO1 probe 
 
Scheme 1. Reduction of the substrate to yield fluorescent 4-MU 
 
To create the NQO1 probe, a fluorogenic enzyme substrate probe was rationally designed 
based on the ‘quinone trimethyl lock’ system [24] in which 4-MU was attached to a quinone 
acid via an ester link. This conjugation reversibly quenches the fluorescence of the 4-MU. 
Upon redox ‘activation’ by NQO1, the quinone moiety is reduced to its corresponding 
hydroquinone. The unfavorable steric interaction caused by the presence of the trimethyl lock 
encourages spontaneous lactonisation thereby releasing the highly fluorescent 4-MU (Scheme 
1). In our experiments, the novel substrate was synthesised by coupling 3-methyl-3-(2,4,5-
trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid [25] to 4-MU in the presence of DCC 
and DMAP (Scheme 2). 
 
  
Scheme 2. Synthesis of substrate 4-Methyl-2-oxo-2H-chromen-7-yl 3-methyl-3-(2,4,5-trimethyl-3,6-
dioxocyclohexa-1,4-dienyl)butanoate 
 
Computational chemistry suggested that the conjugate should be an effective substrate for 
NQO1 as it interacts favorably with the bound co-factor FADH2 and is stabilized by some of 
the active site residues of the NQO1 enzyme (Figure 1). In addition, the position of the 
substrate in the active site and its close proximity and orientation to the bound co-factor 
FADH2 suggested that it should be able to undergo a hydride transfer reaction from the co-
factor to the quinone oxygen of the substrate, resulting in the formation of the ‘activated’ 
hydroquinone species. 
To determine the efficacy of human NQO1 in cleaving the substrate, the apparent kinetic 
parameters were measured by measuring release of 4-MU from the quenched substrate in the 
presence of NQO1 (Figure 2).  Kinetics were measured for substrate concentrations between 
1 and 50µM.  As can be seen in Figure 2a, the reaction was extremely rapid and was >90% 
complete within 5 minutes with the presence of relatively small amounts of NQO1.  In 
comparison, there was little background MTL8-252 degradation.  When fitted to the 
Michaelis-Menten equation (Figure 2b), Km was found to be 5.06 ± 1.31 µM, Vmax to be 101.5 
± 8.3 µmol min-1mg hNQO1-1 and kcat to be 157.4 ± 12.9 s
-1.  The kcat/Km of 3.11 ± 0.16 x 10
5 
M-1s-1 indicated that cleavage of MTL8-252 by NQO1 in non-saturated solutions was at 
reaction rates comparable to other excellent NQO1 substrates reported in the literature 
[20,26–28]. 
 
 
         
Figure 1. The binding mode and interaction of substrate in the FAD-binding site of NQO1. The carbonyl 
quinone moiety and FADH2 are in close proximity (C=O1---N5H, 3.31Å). This indicates that hydride transfer 
may occur resulting in the reduction of the probe and ultimate release of the fluorophore. The substrate binding 
is further stabilised by active site residues Trp-105, Phe-106, Gly-149, Gly-150, Met-154, Tyr-155 and His-161. 
 
    
 
 
Figure 2. Kinetics of enzymatic reduction of the substrate.   (A) 4-MU production from MTL8-252  by 
NQO1.  Values are the average of duplicate readings from one of five experiments.  To a reaction mixture 
containing substrate (20 µM) and NADH (500 µM) in HBSS was added 20ng purified human NQO1. 
Fluorescence at 450nm was monitored as described in materials and methods. (B) Kinetic plot of NQO1 with 
MTL8-252 as substrate. Values represent mean ± SD of 5 experiments. 
 
MTL8-252 is effective and specific in detecting NQO1 in live cells 
While there are currently efficient ways to detect NQO1 in cell extracts [19] and in cells for 
microscopy/flow cytometry [16,20], these retain the signal in the cell and/or require cell lysis 
for NQO1 quantitation.  This restricts NQO1 assays to being single measurements and 
reduces the ability of researchers to use assays with multiple outputs.  Since MTL8-252 can 
easily diffuse across cell membranes, we wanted to determine whether it would be capable of 
measuring NQO1 activity in live cells, and whether the substrate was subject to non-specific 
breakdown when exposed to the intracellular environment. 
To assess whether the MTL8-252 could be used to detect NQO1 in live cells, we initially 
measured MTL8-252 conversion in NQO1-negative V79 Chinese hamster lung epithelial 
cells transfected with either NQO1 (hDT7 cells) or an empty vector (F179 cells) [23]. It was 
found that there was a clear increase in the yield of the 4-MU product from MTL8-252 in 
hDT7 cells compared to F179 cells, and that the difference between the two cells lines was 
evident within 1 minute of starting the reaction.  Indeed, there was approximately a 100-fold 
increase in the initial rate of formation of 4-MU product in the hDT7 cells relative to the 
F179 cells (Figure 3).  While there was an increase in fluorescence intensity over time in the 
F179 cells, it was substantially lower than that from NQO1-positive hDT7 cells, and was 
minimal at the 10 minute timepoint.  We subsequently used the 10 minute timepoint for all 
experiments. Inhibition of the reaction with the competitive NQO1 inhibitor dicoumarol [29] 
and the irreversible NQO1 inhibitor ES936 [30,31] but not the 1-electron flavoenzyme 
inhibitor DPI showed that the response in hDT7 cells was NQO1-specific (Figure 4). 
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Figure 3. Specific detection of NQO1 in live cells.  2 x 105 V79 cells transfected with human NQO1 (hDT7) or 
empty vector (F179) were collected from 90% confluent cultures and suspended in HBSS containing 10 µM 
MTL8-252.  At the indicated time points, samples were filtered through a 0.2 µm Thomsen X-Treme vial and 
100 µl of filtrate added to 2.5 µl 2M Na2CO3 for reading of 4-MU fluorescence (λex= 360 nm; λem = 450 nm).  
All samples were tested in duplicate.  Results show the mean and range of results for one experiment, and are 
representative of three independent experiments.   
  
 
Figure 4.  The assay is specific to NQO1. 5 x 104 hDT7 (NQO1+) or F179 (NQO1-) cells were incubated with 
5 μM MTL8-252 with 20 μM DPI, 50 μM dicoumarol or 40 μM ES936 at 37ºC for 10 min.  The reaction mix 
was filtered through a 0.2 μm PTFE filter and 100 μl of filtrate was admixed with 2 M aqueous Na2CO3 before 
reading 4-MU fluorescence in the fluorimeter.  All samples were tested in duplicate and data represents mean ± 
range.   
 
MTL8-252 detects NQO1 in NQO1-expressing cancer cell lines 
Having demonstrated that MTL8-252 was capable of detecting NQO1 activity in cell lines 
genetically manipulated to express the enzyme, we determined whether it could detect 
differences in naturally-occurring tumoral NQO1 levels.  Cancer cell lines with varying 
levels of NQO1 expression were used: RT112 and PC3 were used as examples of high 
NQO1-expressing cancers, BE was used as an example of cancers containing the C609T 
mutation which leads to reduced NQO1 protein levels, and 293T cells were used as an 
example of NQO1-negative cells.  Each was tested in the assay with or without NQO1 
inhibition (Figure 5a).  It was found that in all cell lines NQO1 status correlated with 4-MU 
release, and that it was inhibited by the prototypical NQO1 inhibitor dicoumarol.  We further 
investigated the responses of RT112 in the presence of a variety of inhibitors known to affect 
various stages of the redox pathways: the mechanism-based irreversible NQO1 inhibitor 
ES936 [26], the NQO2 inhibitor 9aa [32], superoxide dismutase which converts superoxide 
into hydrogen peroxide [33], capsaicin which inhibits NADH-dependent ubiquinone redox 
cycling [34] and sodium azide, which inhibits mitochondrial respiration [35].  It was found 
that only ES936 and dicoumarol inhibited the conversion of MTL8-252, confirming its 
specificity for NQO1 (Figure 5b). 
  
Figure 5.  MTL8-252 reliably detects NQO1 in several cancer cell lines.  (A) 5 x 104 cells of the indicated 
cell lines were incubated with 5 μM MTL8-252 for 10 minutes either in the presence or absence of 50 μM 
dicoumarol, and 4-MU fluorescence subsequently measured. (B) 5 x 104 RT112 cells were incubated with 5 μM 
MTL8-252 for 10 minutes either in the absence or presence respectively of 50 μM dicoumarol, 40 μM ES936, 
100 nM 9aa, 1 U superoxide dismutase (SOD), 200 μM capsaicin or 10 mM sodium azide (Na Azide). All show 
mean and range of triplicate readings and are representative of 2 or 3 independent experiments for B and A 
respectively. Comparisons performed with Student’s t-tests. ** = p <0.01, * = p <0.05   (C)  Western blot 
showing NQO1 expression in each of the cell lines used. Western blot performed as described in materials and 
methods. 
 
 
MTL8-252 in live cells is as or more sensitive than the Prochaska assay of cell extracts.  
To determine the sensitivity of the assay compared to the current standard Prochaska assay 
(Figure 6a, b), and the NADH consumption assay (Figure 6c, d), and to test whether substrate 
was quantitative, the assays were tested in parallel both with isolated NQO1 enzyme and with 
live cells. When assaying enzyme alone it was found that the MTL8-252 assay was 
comparable to the Prochaska assay, with consistently slightly higher sensitivity (Figure 6a).  
Consumption of NADH as shown by a reduction in fluorescence was found to be the most 
effective method of quantifying NQO1, with sensitivity higher than both other assays (Figure 
6 c, d).  This is in keeping with the very low Km and high Vmax of menadione [28] and the 
sensitivity of direct measurement of NADH by fluorescence.   When testing cells, RT112 
cells were serially diluted and either frozen in dry ice to produce cell extracts for the 
Prochaska assay or used directly in the live cell assay.  It was found that the Prochaska assay 
reliably detected down to 2 x 104 RT112 cells, while the live cell assay could detect down to 
1 x 104 cells (Figure 6b) and exhibited superior signal-noise ratios at lower cell numbers, an 
important consideration in applications where cell numbers in analytical samples may be 
limited. Hence MTL8-252 substrate was suitable for assaying enzyme alone, but it was 
particularly effective in determining NQO1 levels in live cells.  
 
 
 
 
Figure 6.  Comparison between the current assay, the Prochaska assay, and the NADH consumption 
assay in quantitation of NQO1.  (A) NQO1 enzyme was serially diluted and incubated either with 330 µM 
NADH and the MTL8-252 substrate (left y axis), or with Prochaska assay reagents (right y axis) for 10 min.  
NADH was degraded with HCl, and 4-MU measured in a UV fluorimeter.  Prochaska assay was performed as 
per materials and methods.  (B)  RT112 cells were resuspended to 107 cells/ml and serially diluted. Half of the 
serial dilution was frozen on dry ice for use in the Prochaska assay, as described in the Experimental Section, 
and half was used in the direct live cell assay.  For the live cell assay, cells were incubated with 5 μM MTL8-
252 at 37ºC for 10 min.  The reaction mix was filtered through a 0.2 μm PTFE filter and 100 μl of filtrate was 
admixed with 2 µl of 2M aqueous Na2CO3 before reading 4-MU fluorescence in the fluorimeter.  (C) NQO1 
enzyme was serially diluted as previously and incubated with 500 µM NADH and the MTL8-252 substrate. 
After 10 minutes, 2.5 µl 2M Na2CO3 was added per 100 µl assay fluid and fluorescence read as previously.  
Dotted lines indicate approximate limits of quantitation. (D) Serial dilutions of NQO1 enzyme were incubated 
with 50 µM menadione, 5 µM FAD and 200 µM NADH. Reduction of NADH to NAD+ was followed by the 
quantitating NADH fluorescence (λex. 340nm, λem. 440nm).   All samples were tested in duplicate.  Each panel 
is representative of at least two independent experiments.   
A B 
  
MTL8-252 is non-toxic 
We next investigated whether the use of MTL8-252 to determine NQO1 activity in live cells 
would affect their viability. RT112 cells were cultured in DMEM10 lacking phenol red and 
MTL8-252 was added either at the standard concentration used for assays (5 μM) or at a ten-
fold higher concentration (50 μM).  The standardized assay was performed as described 
above, with a small amount of medium being drawn off for measurement at intervals for 
measurement of 4-MU.  It was found that up to 1hr after addition of the substrate there were 
clear differences between samples with or without cells.  By 12 h post-addition the substrate 
was reduced to its constituent 4-MU and lactone group independent of the presence of NQO1 
(Figure 7a). Cell growth was followed to confluence (72 hours post-seeding). It was found 
that MTL8-252 and its products had no detectable effect on cell growth (Figure 7b).  Hence 
MTL8-252 is unique in that it can be used to quantitate NQO1 levels in live cells, and does 
not appear to affect viability.  
 
 
Figure 7.  MTL8-252 is non-toxic and can be used to measure NQO1 activity in live cells.  RT112 cells 
were seeded at 3 x 103 cells per well into a 96 well plate and incubated with either 5 μM or 50 μM MTL8-252.   
(A) 200 μl of medium from wells containing 5 μM MTL8-252 was taken at the indicated intervals from wells 
with or without cells, and immediately filtered. 4-MU was then measured by fluorescence. (B) Cell viability was 
measured by CellTiterGlo at 24 h intervals in the presence of either 5 μM or 50 μM MTL8-252.  All assays used 
triplicate wells. Samples compared using Student’s t-test.  ** =  p < 0.01. 
  
MTL8-252 and its fluorescent products are not retained by live cells. 
Our work had so far indicated that MTL8-252 was capable of being catalysed very rapidly by 
live cells and its fluorescent product measured in the cell medium.  This strongly supported 
MTL8-252 and its cleavage products being able to freely move across cell membranes.  To 
examine whether this was indeed the case or whether the compound was retained in the cell, 
hDT7 and F179 cells were incubated with 10 µM MTL8-252 for 5 minutes, then centrifuged 
and the fluid phase removed for reading of NQO1 activity as previously.  The cells were 
washed rapidly to remove any remaining fluid, then washed twice with a 5 minute incubation 
and 5 minute centrifugation at each wash, and the wash buffers read for 4-MU.  The cells 
were then lysed and incubated with an excess of NADH and NQO1 enzyme to allow any 
remaining MTL8-252 to be fully enzymatically cleaved, and fluorescence once again 
measured.  As can be seen in figure 8, the hDT7 cells were strongly positive for NQO1, with 
the control F179 cells giving a low background reading.  4-MU readings in the wash buffers 
were negligible for both cell types.  This is in keeping with the reported retention time of 4-
MU in the cells of t1/2 of 2 seconds or less [36].  When the cells were lysed after the third 
wash and MTL8-252 reacted to completion by the addition of excess NQO1 and NADH, it 
was found that remaining fluorescence was at background levels, indicating that minimal 
MTL8-252 was retained in the cells. 
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Figure 8.  Minimal MTL8-252 is retained inside of cells.  5 x 104 F179 or hDT7 cells were assayed for NQO1 
activity with MTL8-252 for 5 min as described in the materials and methods, and 200µl washes examined for 4-
MU by detecting fluorescence as previously.  Cells were lysed a total of 30 minutes after the initial incubation 
and assayed for MTL8-252 as described in the materials and methods.  All data represent n=3. Samples 
compared using Student’s t-test.  *** =  p < 0.001. 
 
  
Conclusions 
These data show that dicoumerol-inhibitable activation of MTL8-252 can be used as the basis 
of a method for discriminating between various levels of NQO1 activity in live cells. The 
kinetic studies illustrate that MTL8-252 is a very effective and rapid substrate for NQO1 
which can allow the detection of elevated levels of NQO1 in relatively small numbers of cells 
within less than 10 minutes.  The 4-MU is not entrapped within the cells and so the reaction 
is conveniently stopped and potentially interfering cellular debris removed in a simple 
filtration step. This method permits sensitive, quantitative measurement to be made which is 
particularly important in cases where the level of over-expression of NQO1 is incremental in 
cells under test relative to “basal” levels.  It should be noted that the live cell assay is a 
measure of NQO1 activity and as such will reflect intracellular changes that will affect NQO1 
activity such as intracellular NAD(P)H availability.  The test has the advantage of not 
affecting cell viability, and the high cell membrane permeability means that cells can be 
assayed for NQO1 activity prior to use in assays such as flow cytometry, which require intact 
and/or live cells.  MTL8-252 forms a unique and important tool in addition to the alternative 
trimethyl lock probes which are retained in the cells and which are designed for the 
visualisation of NQO1-high cells [20].   
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